PubRank

D W Denning

Author PubWeight™ 198.77‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2001 12.73
2 Practice guidelines for diseases caused by Aspergillus. Infectious Diseases Society of America. Clin Infect Dis 2000 3.70
3 Laboratory diagnosis of invasive aspergillosis. Lancet Infect Dis 2005 3.31
4 In vitro activity of SCH-56592 and comparison with activities of amphotericin B and itraconazole against Aspergillus spp. Antimicrob Agents Chemother 1997 2.99
5 Efficacy of SCH-56592 in a temporarily neutropenic murine model of invasive aspergillosis with an itraconazole-susceptible and an itraconazole-resistant isolate of Aspergillus fumigatus. Antimicrob Agents Chemother 1997 2.79
6 Aspergillus flavus: human pathogen, allergen and mycotoxin producer. Microbiology 2007 2.49
7 Adverse events associated with itraconazole in 189 patients on chronic therapy. J Antimicrob Chemother 1990 2.49
8 High prevalence of antifungal resistance in Candida spp. from patients with AIDS. J Antimicrob Chemother 1994 2.21
9 The invasive and saprophytic syndromes due to Aspergillus spp. Med Mycol 2005 2.21
10 Fluconazole resistance in Candida in patients with AIDS--a therapeutic approach. J Infect 1993 2.10
11 Efficacy of LY303366 against amphotericin B-susceptible and -resistant Aspergillus fumigatus in a murine model of invasive aspergillosis. Antimicrob Agents Chemother 1998 2.04
12 Allergic bronchopulmonary aspergillosis: review of literature and proposal of new diagnostic and classification criteria. Clin Exp Allergy 2013 2.03
13 Antifungal drug resistance in Aspergillus. J Infect 2000 2.01
14 Fluconazole-resistant candidosis in an HIV cohort. AIDS 1994 1.95
15 Underlying conditions in chronic pulmonary aspergillosis including simple aspergilloma. Eur Respir J 2010 1.87
16 Increasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computed tomography scans in patients with neutropenia. J Clin Oncol 2001 1.85
17 Hydrocortisone-enhanced growth of Aspergillus spp.: implications for pathogenesis. Microbiology 1994 1.82
18 Invasive aspergillosis in patients with AIDS. Clin Infect Dis 1994 1.80
19 Multicenter evaluation of the reproducibility of the proposed antifungal susceptibility testing method for fermentative yeasts of the Antifungal Susceptibility Testing Subcommittee of the European Committee on Antimicrobial Susceptibility Testing (AFST-EUCAST). Clin Microbiol Infect 2003 1.79
20 Resistance to fluconazole in Candida albicans from AIDS patients correlated with reduced intracellular accumulation of drug. FEMS Microbiol Lett 1995 1.66
21 Molecular typing by random amplification of polymorphic DNA and M13 southern hybridization of related paired isolates of Aspergillus fumigatus. J Clin Microbiol 1996 1.65
22 Azole cross-resistance in Aspergillus fumigatus. Antimicrob Agents Chemother 2002 1.61
23 Prospective multicenter international surveillance of azole resistance in Aspergillus fumigatus. Emerg Infect Dis 2015 1.61
24 Interaction of azoles with rifampin, phenytoin, and carbamazepine: in vitro and clinical observations. Clin Infect Dis 1992 1.58
25 Invasive infection due to penicillium species other than P. marneffei. J Infect 2002 1.58
26 Polymorphisms in toll-like receptor genes and susceptibility to pulmonary aspergillosis. J Infect Dis 2008 1.57
27 Infrared body temperature measurement of mice as an early predictor of death in experimental fungal infections. Lab Anim 2003 1.53
28 In-vitro activity of the new triazole D0870 compared with amphotericin B and itraconazole against Aspergillus spp. J Antimicrob Chemother 1993 1.51
29 Lack of correlation of in vitro amphotericin B susceptibility testing with outcome in a murine model of Aspergillus infection. J Antimicrob Chemother 2000 1.50
30 Need for alternative trial designs and evaluation strategies for therapeutic studies of invasive mycoses. Clin Infect Dis 2001 1.48
31 Peripheral symmetrical gangrene successfully treated with epoprostenol and tissue plasminogen activator. Lancet 1986 1.44
32 Aspergillus fungemia: report of two cases and review. Clin Infect Dis 1995 1.42
33 New and emerging treatments for fungal infections. J Antimicrob Chemother 2008 1.42
34 Ulcerative tracheobronchitis after lung transplantation. A new form of invasive aspergillosis. Am Rev Respir Dis 1991 1.40
35 Activity of SCH 56592 compared with those of fluconazole and itraconazole against Candida spp. Antimicrob Agents Chemother 1997 1.39
36 Endemic mycoses: a treatment update. J Antimicrob Chemother 1999 1.39
37 Performance of cryptococcus antigen latex agglutination kits on serum and cerebrospinal fluid specimens of AIDS patients before and after pronase treatment. J Clin Microbiol 1991 1.38
38 CADRE: the Central Aspergillus Data REpository. Nucleic Acids Res 2004 1.36
39 Azole resistance in allergic bronchopulmonary aspergillosis and Aspergillus bronchitis. Clin Microbiol Infect 2009 1.32
40 Amphotericin B resistance testing of Candida spp.: a comparison of methods. J Antimicrob Chemother 1997 1.32
41 Administering amphotericin B--a practical approach. J Antimicrob Chemother 1994 1.32
42 Aspergillus wound infection following laparostomy. J Infect 1996 1.31
43 Efficacy of isavuconazole, voriconazole and fluconazole in temporarily neutropenic murine models of disseminated Candida tropicalis and Candida krusei. J Antimicrob Chemother 2008 1.31
44 Invasive yeast infections other than Candida spp. in acute leukaemia. J Hosp Infect 1999 1.29
45 Acute myelopathy associated with primary infection with human immunodeficiency virus. Br Med J (Clin Res Ed) 1987 1.28
46 In-vitro activities of amphotericin B, itraconazole and voriconazole against 150 clinical and environmental Aspergillus fumigatus isolates. J Antimicrob Chemother 1998 1.27
47 Molecular genetics in Aspergillus fumigatus. Curr Opin Microbiol 2000 1.27
48 Pathogenicity of Aspergillus fumigatus mutants assessed in Galleria mellonella matches that in mice. Med Mycol 2010 1.26
49 Fluconazole for the management of invasive candidiasis: where do we stand after 15 years? J Antimicrob Chemother 2006 1.26
50 Scedosporium prolificans, a multi-resistant fungus, from a U.K. AIDS patient. J Infect 1995 1.23
51 In vivo activity of amphotericin B lipid complex in immunocompromised mice against fluconazole-resistant or fluconazole-susceptible Candida tropicalis. Antimicrob Agents Chemother 2000 1.21
52 In vitro activity of the echinocandin antifungal agent LY303,366 in comparison with itraconazole and amphotericin B against Aspergillus spp. Antimicrob Agents Chemother 1998 1.19
53 Post-operative aspergillosis. Clin Microbiol Infect 2006 1.19
54 Comparison of skin prick tests with specific serum immunoglobulin E in the diagnosis of fungal sensitization in patients with severe asthma. Clin Exp Allergy 2009 1.18
55 Liposomal amphotericin B (AmBisome) therapy in invasive fungal infections. Evaluation of United Kingdom compassionate use data. Arch Intern Med 1995 1.17
56 Reduced accumulation of drug in Candida krusei accounts for itraconazole resistance. Antimicrob Agents Chemother 1996 1.15
57 Evidence of multiple extracellular phospholipase activities of Aspergillus fumigatus. Infect Immun 1996 1.14
58 In-vitro activity of voriconazole against Aspergillus spp. and comparison with itraconazole and amphotericin B. J Antimicrob Chemother 1998 1.14
59 Atypical eumycetoma caused by Phialophora parasitica successfully treated with itraconazole and flucytosine. Br J Dermatol 1997 1.13
60 Comparison of in vitro activity of liposomal nystatin against Aspergillus species with those of nystatin, amphotericin B (AB) deoxycholate, AB colloidal dispersion, liposomal AB, AB lipid complex, and itraconazole. Antimicrob Agents Chemother 1999 1.12
61 Species differentiation by internally transcribed spacer PCR and HhaI digestion of fluconazole-resistant Candida krusei, Candida inconspicua, and Candida norvegensis strains. J Clin Microbiol 1997 1.11
62 Susceptibility testing of Aspergillus flavus: inoculum dependence with itraconazole and lack of correlation between susceptibility to amphotericin B in vitro and outcome in vivo. Antimicrob Agents Chemother 2001 1.10
63 Efficacy of oral saperconazole in systemic murine aspergillosis. J Med Vet Mycol 1996 1.10
64 In vitro activity of a new echinocandin, LY303366, and comparison with fluconazole, flucytosine and amphotericin B against Candida species. Clin Microbiol Infect 2001 1.09
65 Itraconazole therapy for chronic coccidioidal meningitis. Ann Intern Med 1990 1.07
66 When to use fluconazole. Lancet 1995 1.07
67 Skin rash after triple vaccine. Arch Dis Child 1987 1.07
68 Treatment of Absidia corymbifera infection in mice with amphotericin B and itraconazole. J Antimicrob Chemother 2001 1.06
69 Treatment of coccidioidal meningitis with fluconazole. Rev Infect Dis 1990 1.06
70 Excess mortality, length of stay and cost attributable to candidaemia. J Infect 2009 1.04
71 Inhibition and interaction of cytochrome P450 of Candida krusei with azole antifungal drugs. J Med Vet Mycol 1997 1.03
72 Bioassay for serum itraconazole concentrations using hydroxyitraconazole standards. Antimicrob Agents Chemother 1994 1.01
73 Mannose-binding lectin gene polymorphisms as a susceptibility factor for chronic necrotizing pulmonary aspergillosis. J Infect Dis 2001 1.00
74 Cutaneous Mycobacterium thermoresistibile infection in a heart transplant recipient. Rev Infect Dis 1989 1.00
75 Unilateral wheeze caused by pseudomembranous aspergillus tracheobronchitis in the immunocompromised patient. Thorax 1993 1.00
76 In vitro activity of D0870 compared with those of other azoles against fluconazole-resistant Candida spp. Antimicrob Agents Chemother 1995 0.99
77 HIV antigenaemia in acute HIV infection. Lancet 1987 0.98
78 A phase III study of recombinant human interferon gamma to prevent opportunistic infections in advanced HIV disease. AIDS Res Hum Retroviruses 2001 0.97
79 What can comparative genomics tell us about species concepts in the genus Aspergillus? Stud Mycol 2007 0.96
80 Candida glabrata oesophagitis in a patient without HIV infection. Eur J Clin Microbiol Infect Dis 2000 0.96
81 Comparison of D0870, a new triazole antifungal agent, to fluconazole for inhibition of Candida albicans cytochrome P-450 by using in vitro assays. Antimicrob Agents Chemother 1996 0.96
82 Isolation of Candida norvegensis from clinical specimens: four case reports. Clin Infect Dis 1996 0.96
83 Invasive aspergillosis: current and future challenges in diagnosis and therapy. Clin Microbiol Infect 2004 0.95
84 An algorithmic approach to aspergillus sinusitis. J Laryngol Otol 1994 0.95
85 Diagnosis of infections with Shiga-like toxin-producing Escherichia coli by use of enzyme-linked immunosorbent assays for Shiga-like toxins on cultured stool samples. J Med Microbiol 1994 0.95
86 Current trends in the detection of antigenaemia, metabolites and cell wall markers for the diagnosis and therapeutic monitoring of fungal infections. Med Mycol 1998 0.94
87 Candida inconspicua, a fluconazole-resistant pathogen in patients infected with human immunodeficiency virus. Clin Infect Dis 1997 0.94
88 In vitro activities of terbinafine against Aspergillus species in comparison with those of itraconazole and amphotericin B. Antimicrob Agents Chemother 2001 0.94
89 Invasive aspergillosis as an opportunistic infection in nonallografted patients with multiple myeloma: a European Organization for Research and Treatment of Cancer/ Invasive Fungal Infections Cooperative Group and the Intergroupe Français du Myélome. Clin Infect Dis 2000 0.93
90 High-level expression of cyp51B in azole-resistant clinical Aspergillus fumigatus isolates. J Antimicrob Chemother 2012 0.92
91 Neuralgic amyotrophy due to parvovirus infection. J Neurol Neurosurg Psychiatry 1987 0.92
92 Voriconazole plasma monitoring. Arch Dis Child 2008 0.92
93 DNA typing of epidemiologically-related isolates of Aspergillus fumigatus. Epidemiol Infect 1995 0.92
94 Activity of micafungin (FK463) against an itraconazole-resistant strain of Aspergillus fumigatus and a strain of Aspergillus terreus demonstrating in vivo resistance to amphotericin B. J Antimicrob Chemother 2003 0.91
95 Oxygen requirements of Aspergillus species. J Med Microbiol 1994 0.91
96 In vitro activity of the new triazole BMS-207147 against Aspergillus species in comparison with itraconazole and amphotericin B. Antimicrob Agents Chemother 2000 0.91
97 Itraconazole therapy for nonmeningeal coccidioidomycosis: clinical and laboratory observations. J Am Acad Dermatol 1990 0.91
98 Karyotyping of fluconazole-resistant yeasts with phenotype reported as Candida krusei or Candida inconspicua. Int J Syst Bacteriol 1996 0.91
99 Micafungin alone or in combination with other systemic antifungal therapies in hematopoietic stem cell transplant recipients with invasive aspergillosis. Transpl Infect Dis 2008 0.90
100 Fungal contamination of bedding. Allergy 2006 0.90
101 US experience with itraconazole in Aspergillus, Cryptococcus and Histoplasma infections in the immunocompromised host. Chemotherapy 1992 0.90
102 Pattern recognition receptor expression is not impaired in patients with chronic mucocutanous candidiasis with or without autoimmune polyendocrinopathy candidiasis ectodermal dystrophy. Clin Exp Immunol 2009 0.89
103 Rapid genotyping of Escherichia coli O157 isolates by random amplification of polymorphic DNA. Eur J Clin Microbiol Infect Dis 1996 0.88
104 High incidence of antifungal drug resistance in Candida tropicalis. Int J Antimicrob Agents 1996 0.88
105 Skull base osteitis following fungal sinusitis. J Laryngol Otol 1998 0.88
106 In vitro interaction of terbinafine with itraconazole, fluconazole, amphotericin B and 5-flucytosine against Aspergillus spp. J Antimicrob Chemother 2002 0.88
107 Successful treatment of sinusitis caused by Cunninghamella bertholletiae. Clin Infect Dis 1994 0.87
108 Optimising antifungal therapy for individual patients. Intern Med J 2004 0.86
109 Performance of two Aspergillus IgG EIA assays compared with the precipitin test in chronic and allergic aspergillosis. Clin Microbiol Infect 2013 0.86
110 Cyclosporine and itraconazole interaction in heart and lung transplant recipients. Ann Intern Med 1990 0.86
111 What the Aspergillus genomes have told us. Med Mycol 2005 0.86
112 Molecular typing of Aspergillus terreus by random amplification of polymorphic DNA. Eur J Clin Microbiol Infect Dis 1999 0.86
113 Fungal infections: a survey of laboratory services for diagnosis and treatment. Commun Dis Rep CDR Rev 1996 0.85
114 Mycoses in AIDS patients. J Med Vet Mycol 1994 0.85
115 Cryptococcal meningitis in the immunocompromised host: intracranial hypertension and other complications. Mycopathologia 1999 0.84
116 Cure of chronic invasive sinus aspergillosis with oral saperconazole. J Med Vet Mycol 1995 0.84
117 Failure of single dose amoxycillin as prophylaxis against endocarditis. Br Med J (Clin Res Ed) 1984 0.84
118 Flucytosine therapeutic monitoring: 15 years experience from the UK. J Antimicrob Chemother 2007 0.83
119 Treatment of fungal infection in AIDS. J Antimicrob Chemother 1996 0.83
120 Endocarditis due to Trichosporon beigelii: in vitro susceptibility of isolates and review. Rev Infect Dis 1991 0.83
121 Uncommon invasive mycoses in AIDS. AIDS 1995 0.83
122 Molecular typing of Aspergillus species. J Hosp Infect 1995 0.83
123 Discrepancies associated with the measurement of itraconazole serum concentrations by bioassays. J Antimicrob Chemother 1999 0.82
124 Invasive pulmonary aspergillosis transformed into fatal mucous impaction by immune reconstitution in an AIDS patient. Eur J Clin Microbiol Infect Dis 2005 0.82
125 Antifungal susceptibility testing of fluconazole by flow cytometry correlates with clinical outcome. J Clin Microbiol 2001 0.82
126 Efficacy of caspofungin as salvage therapy for invasive aspergillosis compared to standard therapy in a historical cohort. Eur J Clin Microbiol Infect Dis 2010 0.82
127 Aspergillus fumigatus catalases: cloning of an Aspergillus nidulans catalase B homologue and evidence for at least three catalases. FEMS Immunol Med Microbiol 1999 0.82
128 Detection of Aspergillus in lung and other tissue samples using the MycAssay Aspergillus real-time PCR kit. Can J Microbiol 2011 0.82
129 An aspergilloma caused by Aspergillus flavus. Med Mycol 2008 0.82
130 Standards of care for patients with invasive fungal infections within the United Kingdom: a national audit. J Infect 2009 0.82
131 D-mannitol in cerebrospinal fluid of patients with AIDS and cryptococcal meningitis. J Clin Microbiol 1996 0.81
132 Empiric amphotericin B therapy: the need for a reappraisal. Blood Rev 1993 0.81
133 Detrimental effect of propylene glycol on natural killer cell and neutrophil function. J Pharm Pharmacol 1987 0.81
134 Epidemiology of invasive aspergillosis in European cancer centres. EORTC Invasive Fungal Infections Cooperative Group. Eur J Clin Microbiol Infect Dis 1993 0.81
135 Cytokine profiling of pulmonary aspergillosis. Int J Immunogenet 2006 0.81
136 Comparison of two fluorescent whiteners, Calcofluor and Blankophor, for the detection of fungal elements in clinical specimens in the diagnostic laboratory. Clin Microbiol Infect 2006 0.80
137 Mannose-binding lectin genotype and serum levels in patients with chronic and allergic pulmonary aspergillosis. Int J Immunogenet 2012 0.80
138 Variation in morphotype, karyotype and DNA type of fluconazole resistant Candida albicans from an AIDS patient. J Infect 1998 0.80
139 Fungal infection of the diabetic foot: two distinct syndromes. Diabet Med 2001 0.80
140 Voriconazole-induced photosensitivity: photobiological assessment of a case series of 12 patients. Br J Dermatol 2012 0.80
141 A prominent role for the IL1 pathway and IL15 in susceptibility to chronic cavitary pulmonary aspergillosis. Clin Microbiol Infect 2014 0.80
142 Renal aspergilloma--a case illustrating the problems of medical therapy. Nephrol Dial Transplant 1987 0.79
143 Mixed mould species in laboratory cultures of respiratory specimens: how should they be reported, and what are the indications for susceptibility testing? J Clin Pathol 2011 0.79
144 Burden of serious fungal infection in Nigeria. West Afr J Med 2014 0.79
145 Major variations in Aspergillus fumigatus arising within aspergillomas in chronic pulmonary aspergillosis. Mycoses 2013 0.79
146 Termination of development of D0870. J Antimicrob Chemother 2001 0.78
147 Successful treatment of aspergillus brain abscess in a child with acute lymphoblastic leukemia. Pediatr Hematol Oncol 2000 0.78
148 Aspergillus tracheobronchitis. Clin Infect Dis 1994 0.78
149 Prevalence of chronic pulmonary aspergillosis in patients with tuberculosis from Iran. Eur J Clin Microbiol Infect Dis 2015 0.78
150 Use of the 6-methylsalicylic-acid-synthase gene as a discriminating marker between Aspergillus terreus and Aspergillus flavipes. Folia Microbiol (Praha) 1999 0.78
151 Influenza-like episodes in HIV-positive patients: the role of viral and 'atypical' infections. AIDS 1998 0.78
152 A dose comparison study of a new triazole antifungal (D0870) in HIV-positive patients with oral candidiasis. AIDS 1997 0.78
153 Sub-cutaneous phaeohyphomycosis caused by Cladophialophora devriesii in a United Kingdom resident. Med Mycol 2006 0.77
154 In-vitro activity of D0870, a new triazole antifungal drug, in comparison with fluconazole and itraconazole against Aspergillus fumigatus and Candida krusei. J Antimicrob Chemother 1997 0.76
155 Analysis of UK sera for aflatoxin by enzyme-linked immunosorbent assay. Hum Toxicol 1988 0.76
156 Reduced expression of TLR3, TLR10 and TREM1 by human macrophages in Chronic cavitary pulmonary aspergillosis, and novel associations of VEGFA, DENND1B and PLAT. Clin Microbiol Infect 2014 0.76
157 Mycobacterium chelonae finger infection associated with Raynaud's phenomenon. Ann Rheum Dis 2004 0.76
158 Clinical features of peritoneal tuberculosis. J Infect Dis 1989 0.75
159 Corticosteroids in pneumococcal meningitis. J Antimicrob Chemother 1997 0.75
160 Prophylactic fluconazole and marrow transplantation. N Engl J Med 1992 0.75
161 Neurospora sitophila pulmonary infection in a patient with AIDS. AIDS Patient Care STDS 1997 0.75
162 Idiopathic oedema and diuretics. Postgrad Med J 1987 0.75
163 Hyperbaric oxygen therapy in a woman who declined colostomy. Lancet 1996 0.75
164 In vitro activity of BMS-181184 compared with those of fluconazole and amphotericin B against various candida spp. Antimicrob Agents Chemother 1996 0.75
165 Audit of laboratory mycology services for the management of patients with fungal infections in the northwest of England. J Clin Pathol 2006 0.75
166 Cost implications of alternative treatments for AIDS patients with cryptococcal meningitis. J Infect 1992 0.75
167 Cutaneous childhood sarcoidosis--a rare disease refractory to treatment. Rheumatology (Oxford) 2003 0.75
168 Invasive aspergillosis in a patient with MELAS syndrome. J Neurol Neurosurg Psychiatry 2000 0.75
169 Time to finish with "AIDS"? Lancet 1992 0.75
170 Further problems with theophylline. Lancet 1984 0.75
171 An ELISA method for the rapid and simple determination of aflatoxin in human serum. Food Addit Contam 1988 0.75
172 Antifungal drug susceptibility testing. Working Party of the British Society for Antimicrobial chemotherapy. J Antimicrob Chemother 1995 0.75
173 Colouring agents in medicine for asthmatic children. Lancet 1985 0.75
174 Death due to carbamazepine self-poisoning: remedies reviewed. Hum Toxicol 1985 0.75
175 Polar lipids of Aspergillus fumigatus, A. niger, A. nidulans, A. flavus and A. terreus. Med Mycol 1998 0.75
176 Assessment of therapeutic response of oropharyngeal and esophageal candidiasis in AIDS with use of a new clinical scoring system: studies with D0870. Clin Infect Dis 1999 0.75
177 Oral and cutaneous features of acute human immunodeficiency virus infection. Cutis 1987 0.75
178 Activity of pradimicin BMS-181184 against Aspergillus spp. Int J Antimicrob Agents 1999 0.75
179 Prevalence of phthioic acid in Aspergillus species. J Med Vet Mycol 1997 0.75
180 Advances in invasive fungal infection and antifungal therapy: Introduction. Clin Microbiol Infect 2001 0.75
181 Treatment of HIV-related fluconazole-resistant oral candidosis with D0870, a new triazole antifungal. AIDS 1998 0.75
182 Kawasaki disease and aspirin. Lancet 1983 0.75
183 Should travellers to Asia be vaccinated against Japanese encephalitis? Lancet 1987 0.75
184 [Itraconazole in systemic fungal infections]. Med Klin (Munich) 1991 0.75
185 Characterization of Aspergillus isolates by pyrolysis mass spectrometry. Mycoses 1997 0.75